The trial will focus on idiopathic sudden sensorineural hearing loss (ISSNHL), also called sudden deafness. Read More »

Portola Pharmaceuticals Inc. recently received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) submitted for AndexXa (andexanet alf Read More »

The American Society of Health-System Pharmacists (ASHP) has announced a collaboration with the Institute for Safe Medication Practices (ISMP) for the development of a Medication Safety Certificate Program that will begin in the spring of next year. Read More »

CVS Health today announced that all CVS Pharmacy locations in the state of Washington now have naloxone, the opioid overdose-reversal medicine, available for patients without the need of a prescription. Read More »

Dr. Levi Garraway has been appointed SVP of Global Development & Medical Affairs for the oncology business at Eli Lilly and Company. Read More »

Stratice Healthcare, a health care IT leader providing electronic ordering technology connecting home and durable medical equipment and supplies (HME/DME) providers with medical offices and hospital systems, has announced that it has come to terms on an agreement with CMB Solutions, a nationwide patient support and contact service provider for the home medical equipment industry. Read More »

CVS Health this week announced a collaboration with the YMCA of the USA for the expansion of the Diabetes Prevention Program and the LIVESTRONG Foundation at the YMCA program. Read More »

AbbVie, a biopharmaceutical company that operates worldwide, has announced its 2016 Thriving Student Scholarship Contest. Read More »

Galena Biopharma Inc. as announced that the preclinical data from its NeuVax program was revealed during a presentation given Tuesday at the Progress in Vaccination Against Cancer (PIVAC) Conference that is being held in Winchester, England. Read More »

Recent survey results conducted by North Star Opinion Research and released by an industry association confirm that 60 percent of U.S. employers believe new federal oversight would lead to higher prescription-drug costs. Read More »

A single industry-sponsored meal is enough to sway a doctor to prescribe a brand-name drug rather than a cheaper but just as effective generic, a study by the University of San Francisco has found. Read More »

Morphotek Inc. recently entered a Sponsored Research Agreement (SRA) along with Fox Chase Cancer Center (FCCC) that will lead to the expansion of its efforts to research how efficient immune-based therapies are in relation to the immunosuppressive effects that are caused by tumor shed antigens. Read More »

Antibody product is a potential treatment for Huntington's Disease. Read More »

DelMar Pharmaceuticals Inc. recently presented new data in a research poster called, “Activity of dianhydrogalactitol (VAL-083) in ovarian tumor models, sensitive or resistant to cisplatin” at the 11th Biennial Ovarian Cancer Research Symposium. Read More »

Gate Pharmaceuticals Inc. today announced that its subsidiary, Jade Therapeutics, has received a second year of funding from the U.S. Army Medical Research and Material Command (USAMRMC) for a total of $448,185 to develop proprietary thiolated hyaluronic acid for use as an ocular bandage film. Read More »

DelMar Pharmaceuticals Inc. recently partnered with Accurexa Inc. for the development of a novel formulation that will treat brain cancer and other solid tumors. Read More »

Valeant Pharmaceuticals International recently acquired the necessary lender approval for a credit facility amendment. Read More »

Collegium Pharmaceuticals Inc. announced that an independent review of Xtampza ER will be published in The Journal of the American Medical Association (JAMA). Read More »

ProclaRx recently appointed Doug Martin as its new COO, assigning him strategic planning, compliance and coordination of R&D duties. Read More »

Foam Pharmaceuticals Ltd., a clinical stage specialty pharmaceutical company dedicated to the development and commercialization of topical foams to fill unmet dermatology needs, will be releasing the results of its Phase 2 FMX103 clinical trial on Sept. 12. Read More »